Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023
CAMBRIDGE, UK, 2 November 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology’s Kidney Week in Philadelphia, from 2-5 November 2023.
Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function. MTX652 targets USP30, a deubiquitylating (DUB) enzyme uniquely localized to the mitochondria that removes ubiquitin groups and is a negative regulator of the PINK1/Parkin pathway and mitophagy. Mitophagy is a quality control system that ensures dysfunctional mitochondria are removed.
Pau Aceves, MS, MSc, PharmD., Head of Clinical Pharmacology and Pharmacometrics, Mission Therapeutics, commented: We look forward to presenting our latest Phase 1 and Modelling & Simulation results on MTX652 for the treatment of acute kidney injury (AKI). The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
Details of the presentation are as follow:
Presentation Title: MTX652, a Novel Selective USP30 Inhibitor for the Treatment of AKI: Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections
Session Name: Onconephrology and Precision Pharmacology
Session Date: Thursday, November 2nd, 2023
Presentation Time: 4:48 PM - 4:57 PM
Presenter: Pau Aceves, MS, MSc, PharmD., Head of Clinical Pharmacology and Pharmacometrics
Location: Room 107, Pennsylvania Convention Center
Mission has completed its first Phase I clinical study with MTX652, in which it demonstrated a highly encouraging safety, tolerability and pharmacokinetic profile. A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.
